- Thyme (/ t aɪ m /) is the herb (dried aerial parts) of some members of the genus Thymus of aromatic perennial evergreen herbs in the mint family Lamiaceae.Thymes are relatives of the oregano genus Origanum.
- TYME continues to develop a strong pipeline of cancer metabolism-based therapies for advanced cancers. We are focusing on metastatic and hard-to-treat cancers for which current therapies are inadequate. We believe that targeting cancer’s metabolism by disrupting protein synthesis and increasing oxidative stress has advantages over existing.
TYME ('Take Your Money Everywhere') is an ATM/interbank network in Florida, Wisconsin and the Upper Peninsula of Michigan.It was organized in 1975 by First Wisconsin National Bank, Marshall & Ilsley, Marine Bank of Milwaukee, and Midland National Bank. Tyme Technologies, Inc. Common Stock (TYME) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
English[edit]
Noun[edit]
tyme (countable and uncountable, pluraltymes)
- Archaic spelling of time.
- 1588, Ffraunces Morgan, Chancery Procedings, Series II, 222/83[1]:
- in the ſaid Leafe did promyſe and Covenante to and wth the ſaid Giles Allen to build in & vpon the demiſed [premiſſes 4-3] buildings for Tenementes to be errected vpon the premiſſes the ſome of two hundrethe poundes and the ſame to be done and fyniſhed by a certain tyme [5-9]
- 1602, William Combe and John Combe, “The original Conveyance of over a hundred acres of land from William and John Combe to Shakespeare”, in Shakespeare Estate Records[2]:
- the saide John Combe, his heires and assignes, shall and will, from tyme to tyme, and at all tymes herafter, well and sufficientlie save and keepe harmles and indempnified as well the saide fowre yardes of errable lande
- 1629, Charter of Massachusetts Bay[3]:
- And the newe elected Deputie Governor and Assistants, and all other officers to be hereafter chosen as aforesaide from Tyme to Tyme, to take the Oathes to their places respectivelie belonging, before the Governor of the said Company for the Tyme being, vnto which said Governor, Deputie Governor, and assistants
- 2000, Heather J. Kintyre, A Future History: The Tanner Chronicles[4], iUniverse, →ISBN, page 128:
- While Pan slept, the tyme machine was communicating with Skyn regarding Pan.
Anagrams[edit]
- etym, ymet
Middle English[edit]
Etymology 1[edit]
From Old Frenchthym, from Latinthymum, from Ancient Greekθύμον(thúmon).
Alternative forms[edit]
- time, thime
Pronunciation[edit]
- IPA(key): /tim/, /tiːm/
Noun[edit]
tyme (uncountable)
- thyme(plants in the genus Thymus)
Descendants[edit]
- English: thyme
References[edit]
Tyme Iron Pro
- “tī̆me, n.(1).”, in MED Online, Ann Arbor, Mich.: University of Michigan, 2007, retrieved 2018-04-25.
Etymology 2[edit]
From Old Englishtīma, from Proto-Germanic*tīmô. Doublet of demon.
Alternative forms[edit]
- timæ, time, teyme, teme, tyma, tym, tim, tima
Pronunciation[edit]
- IPA(key): /ˈtiːm(ə)/
Tyme Stock Forecast
Noun[edit]
tyme (pluraltymes or tymen)
Sugar Tyme Crab
- time(as a concept)
- A specific duration or period of time; the following specific uses are most common:
- 1407, The Testimony of William Thorpe, pages 40–41
- And with alle these men I was ofte homli and I comownede with hem long tyme and fele, and so bifore alle othir men I chees wilfulli to be enformed bi hem and of hem”
- A reign; a period of time where a person holds an office.
- A lifetime; the time which a person's life is composed of.
- A portion of a larger period of time (e.g. a year; a day), especially a season or yeartide.
- A step or stage of a process or event.
- A ephemeral, momentane or veryshort duration; a point of time or instance.
- 1407, The Testimony of William Thorpe, pages 40–41
- A generic reference to some vaguely-specified or unspecified duration or point of time.
- An occasion, event, or occurence; a specific time.
- times; multipliedby(usually in the plural)
- Specifies the ratio of comparison in a comparative sentence.
- (grammar) Verbal tense; the way time is morphologically marked on a verb.
Derived terms[edit]
Descendants[edit]
- English: time
- Scots: time, teime, tim
- Yola: deemes(plural)
References[edit]
- “tīme, n.(2).”, in MED Online, Ann Arbor, Mich.: University of Michigan, 2007, retrieved 2018-04-25.
Etymology 3[edit]
Noun[edit]
tyme
- Alternative form of teme(“topic”)
BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19.
Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat. Like other TYME agents, TYME-19 affects cellular metabolism. It constrains viral replication after a virus has inserted its genetic blueprint into an infected cell by inhibiting the ability of the virus to use the cells synthetic apparatus to make viral proteins and lipids. As a result, we believe that TYME-19 diminishes the ability of COVID-19 to hijack an infected cell. TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19.
TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication.
About TYME-19
Tyme Curling Iron
TYME-19 is an oral synthetic member of the bile acid family that the Company also uses in its anticancer compound, TYME-18. Because of its expertise in metabolic therapies, the Company was able to identify TYME-19 as a potent, well characterized antiviral bile acid and has performed preclinical experiments establishing effectiveness against COVID-19. Bile acids have primarily been used for liver disease; however, like all steroids, they are messenger molecules that modulate a number of diverse critical cellular regulators. Bile acids modulate lipid and glucose metabolism and can remediate dysregulated protein folding, with potentially therapeutic effects on cardiovascular, neurologic, immune, and other metabolic systems. Some agents in this class also have antiviral properties. In preclinical testing, TYME-19 repeatedly prevented COVID-19 viral replication without attributable cytotoxicity to the treated cells. Previous preclinical research has also shown select bile acids like TYME-19 have had broad antiviral activity.
About Tyme Technologies
Tyme
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
Tyme Technologies
With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19. For more information, visit www.tymeinc.com. Follow us on social media: Facebook, LinkedIn, Twitter, YouTube and Instagram.
Forward-Looking Statements/Disclosure Notice
Tyme Iron Pro
In addition to historical information, this press release contains forward-looking statements under the Private Securities Litigation Reform Act that involve substantial risks and uncertainties. Such forward-looking statements within this press release include, without limitation, statements regarding our drug candidates (including SM-88 and TYME- 18) and their clinical potential and non-toxic safety profiles, our drug development plans and strategies, ongoing and planned preclinical or clinical trials, including the proposed TYME-19 proof-of-concept study, preliminary data results and the therapeutic design and mechanisms of our drug candidates. The words “believes,” “expects,” “hopes,” “may,” “will,” “plan,” “intends,” “estimates,” “could,” “should,” “would,” “continue,” “seeks,” “anticipates,” and similar expressions (including their use in the negative) are intended to identify forward-looking statements. Forward-looking statements can also be identified by discussions of future matters such as: the effect of the novel coronavirus (COVID-19) pandemic and the associated economic downturn and impacts on the Company's ongoing clinical trials and ability to analyze data from those trials; the cost of development and potential commercialization of our lead drug candidate and of other new products; expected releases of interim or final data from our clinical trials; possible collaborations; and the timing, scope, status, objectives and strategy of our ongoing and planned trials; the success of management transitions; and other statements that are not historical. The forward-looking statements contained in this press release are based on management’s current expectations and projections which are subject to uncertainty, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. These statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to be materially different from any historical results and future results, performance or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include but are not limited to: the severity, duration, and economic and operational impact of the COVID-19 pandemic; that the information is of a preliminary nature and may be subject to change; uncertainties inherent in the cost and outcomes of research and development, including the cost and availability of acceptable-quality clinical supply, and in the ability to achieve adequate start and completion dates, as well as uncertainties in clinical trial design and patient enrollment, dropout or discontinuation rates; the possibility of unfavorable study results, including unfavorable new clinical data and additional analyses of existing data; risks associated with early, initial data, including the risk that the final data from any clinical trials may differ from prior or preliminary study data; final results of additional clinical trials that may be different from the preliminary data analysis and may not support further clinical development; that past reported data are not necessarily predictive of future patient or clinical data outcomes; whether and when any applications or other submissions for SM-88 may be filed with regulatory authorities; whether and when regulatory authorities may approve any applications or submissions; decisions by regulatory authorities regarding labeling and other matters that could affect commercial availability of SM-88; the ability of TYME and its collaborators to develop and realize collaborative synergies; competitive developments; and the factors described in the section captioned “Risk Factors” of TYME’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on May 22, 2020, as well as subsequent reports we file from time to time with the U.S. Securities and Exchange Commission available at www.sec.gov.
The information contained in this press release is as of its release date and TYME assumes no obligation to update forward-looking statements contained in this release as a result of future events or developments.